Assessing the landscape of clinical and observational trials involving bioprinting: a scoping review
Briones Y., Pascua B., Tiangco N., Crisostomo I., Casiguran S., Remenyi R.
Laboratory Study, published in 3D Print Med (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- 3D Print Med (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39961914
- PMCID
- PMC11834296
- DOI
- 10.1186/s41205-025-00253-2
- Citations
- 7
Abstract (original English)
Objective Bioprinting is a tissue engineering technique that is rapidly evolving to include complex clinical applications. However, there is limited evidence describing how far bioprinting has progressed past the pre-clinical stage. Thus, we conducted a scoping review to assess the landscape of clinical studies, including interventional and observational trials, involving bioprinting by charting trends in general characteristics, bioprinting application, and trial design. Methods The term "bioprint" and its variants were searched in five trial databases (ICTRP, ScanMedicine, CENTRAL, NIHCC, HCCTD) and two registries (ClinicalTrials.gov, PHRR) on 22 February 2024. This was followed by duplicate removal and dual independent review to finalize the inclusion list. We included trials published in or translated to English mentioning "bioprint" in their design, while we excluded those that did not adhere to our definition of bioprinting. Finally, data were charted and synthesized narratively. Results Of 36 total search records, 11 trials met the inclusion criteria. Registration dates ranged from 2016 to 2023, with China conducting the most trials globally. Four trials had published results, while the remaining were still in progress. Four interventional trials aimed to implant bioprinted tissues made with autologous cells, including blood vessels, trachea, external ear, and wound dres
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.